
Celiac Disease
Description
MarketVue®: Celiac Disease
The MarketVue®: Celiac Disease market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Celiac Disease report is supported by 4 qualitative interviews with key opinion leaders (U.S. Gastroenterologists), a quantitative survey with 20 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• Takeda Pharmaceuticals
• Anokion
• GlaxoSmithKline
• Immunic Therapeutics
• Provention Bio
• Amgen
• Calypso Biotech
• ImmunogenX
• Chugai Pharmaceutical
Key drugs mentioned:
• Budesonide
• Azathioprine
• TAK-101
• KAN-101
• TAK-1227
• GSK3915393
• Vidofludimus calcium / IMU-838
• PRV-015
• CALY-002
• Latiglutenase
• TAK-062
• ZED1227
Please note: the online download version of this report is for a global site license.
Table of Contents
25 Pages
- 1. DISEASE OVERVIEW
- A life-altering autoimmune disease in genetically pre-disposed individuals
- Figure 1.1. Symptomatic presentations of CeD
- Figure 1.2. Villous atrophy in CeD
- Gluten digestion and the ensuing immune response offer numerous targets for drug development
- Figure 1.3. Gluten activation of the immune system and druggable targets
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1. G6 diagnosed prevalent cases of CeD by region
- Table 2.1. Diagnosed prevalent and drug-treated CeD patients in the G6
- The CeD patient population is segmented into three distinct sub-populations
- Overview
- Table 2.2. Description of CeD patient segments
- Figure 2.2. Representation of CeD patient population segments
- 3. DIAGNOSIS AND CURRENT TREATMENT
- Diagnosis overview
- Figure 3.1. Diagnostic pathway for CeD patients
- A gluten-free diet is the current standard of care for CeD
- Figure 3.2. Treatment goals for CeD
- Figure 3.3. Treatment rate among CeD patients
- Figure 3.4. Budesonide and azathioprine patient share in NRCD patients
- Treatment flow for CeD
- Figure 3.5. Treatment algorithm for CeD
- CeD diagnosis and treatment dynamics
- Figure 3.6 Gastroenterologist statement agreement on CeD diagnosis and treatment dynamics
- There is room for improvement over existing treatments
- Table 3.1. Upsides and downsides of current CeD treatments
- Key dynamics that shape treatment and disease management in CeD
- Table 3.2 Must-know CeD treatment dynamics
- The CeD market is poised to solidify with the first drug approval as early as 2025/2026
- Figure 3.7. Important dynamics of CeD market evolution
- 4. UNMET NEED
- Treatment-related unmet needs
- Figure 4.1. Top unmet needs in CeD
- Figure 4.2. Physician-reported unmet needs in CeD
- Physician commentary on unmet needs for novel CeD therapies
- 5. PIPELINE ANALYSIS
- Overview
- Figure 5.1. Number of emerging therapies whose primary clinical trial endpoint addresses unmet needs in CeD
- The pipeline for CeD is active with numerous treatments in Phase 2 clinical development
- Figure 5.2. Percentage of gastroenterologists rating emerging approaches as “promising”
- Table 5.1. Emerging clinical-stage therapies by target
- Gastroenterologists’ perspectives on emerging therapies
- The pipeline for CeD is active with numerous treatments in phase 2 clinical development
- 6. VALUE & ACCESS
- Overview
- Figure 6.1. Reimbursement and access considerations for emerging therapies in CeD
- Figure 6.2. CeD patients by insurance type
- Key insights from the alopecia market
- Table 6.2. Payer coverage requirements of Olumiant to treat alopecia and relevance to CeD
- Improving patient access to new CeD medications will require strategic trial design and patient services
- Figure 6.3. Key considerations for driving access to and uptake of novel CeD therapies
- 7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.